AIM
Price
$9.35
Change
+$0.08 (+0.86%)
Updated
Jul 10, 11:20 AM (EDT)
Capitalization
7.08M
40 days until earnings call
IBIO
Price
$0.84
Change
-$0.00 (-0.00%)
Updated
Jul 10, 11:53 AM (EDT)
Capitalization
13.55M
Interact to see
Advertisement

AIM vs IBIO

Header iconAIM vs IBIO Comparison
Open Charts AIM vs IBIOBanner chart's image
AIM ImmunoTech
Price$9.35
Change+$0.08 (+0.86%)
Volume$600
Capitalization7.08M
iBio
Price$0.84
Change-$0.00 (-0.00%)
Volume$200
Capitalization13.55M
AIM vs IBIO Comparison Chart in %
Loading...
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AIM vs. IBIO commentary
Jul 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AIM is a Hold and IBIO is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 10, 2025
Stock price -- (AIM: $9.27 vs. IBIO: $0.84)
Brand notoriety: AIM and IBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AIM: 68% vs. IBIO: 17%
Market capitalization -- AIM: $7.08M vs. IBIO: $13.55M
AIM [@Biotechnology] is valued at $7.08M. IBIO’s [@Biotechnology] market capitalization is $13.55M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AIM’s FA Score shows that 0 FA rating(s) are green whileIBIO’s FA Score has 1 green FA rating(s).

  • AIM’s FA Score: 0 green, 5 red.
  • IBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, AIM is a better buy in the long-term than IBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AIM’s TA Score shows that 5 TA indicator(s) are bullish while IBIO’s TA Score has 6 bullish TA indicator(s).

  • AIM’s TA Score: 5 bullish, 5 bearish.
  • IBIO’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, IBIO is a better buy in the short-term than AIM.

Price Growth

AIM (@Biotechnology) experienced а +1.11% price change this week, while IBIO (@Biotechnology) price change was +12.89% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.66%. For the same industry, the average monthly price growth was +15.28%, and the average quarterly price growth was +17.95%.

Reported Earning Dates

AIM is expected to report earnings on Aug 19, 2025.

IBIO is expected to report earnings on May 02, 2025.

Industries' Descriptions

@Biotechnology (+8.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBIO($13.5M) has a higher market cap than AIM($7.08M). AIM YTD gains are higher at: -53.182 vs. IBIO (-65.902). AIM has higher annual earnings (EBITDA): -14.33M vs. IBIO (-15.11M). AIM has less debt than IBIO: AIM (2.52M) vs IBIO (3.76M). IBIO has higher revenues than AIM: IBIO (375K) vs AIM (146K).
AIMIBIOAIM / IBIO
Capitalization7.08M13.5M52%
EBITDA-14.33M-15.11M95%
Gain YTD-53.182-65.90281%
P/E RatioN/A0.65-
Revenue146K375K39%
Total CashN/A4.96M-
Total Debt2.52M3.76M67%
FUNDAMENTALS RATINGS
AIM vs IBIO: Fundamental Ratings
AIM
IBIO
OUTLOOK RATING
1..100
2814
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
3693
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBIO's Valuation (27) in the Biotechnology industry is in the same range as AIM (41) in the null industry. This means that IBIO’s stock grew similarly to AIM’s over the last 12 months.

IBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that IBIO’s stock grew similarly to AIM’s over the last 12 months.

IBIO's SMR Rating (98) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that IBIO’s stock grew similarly to AIM’s over the last 12 months.

AIM's Price Growth Rating (36) in the null industry is somewhat better than the same rating for IBIO (93) in the Biotechnology industry. This means that AIM’s stock grew somewhat faster than IBIO’s over the last 12 months.

IBIO's P/E Growth Rating (99) in the Biotechnology industry is in the same range as AIM (100) in the null industry. This means that IBIO’s stock grew similarly to AIM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AIMIBIO
RSI
ODDS (%)
Bearish Trend 9 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
73%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 11 days ago
88%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
AIM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IMTX5.900.28
+4.98%
Immatics NV
ELMD20.510.49
+2.45%
Electromed
QDEL31.570.75
+2.43%
QuidelOrtho Corp
VLTO102.370.04
+0.04%
Veralto Corp
PMN0.39-0.01
-3.02%
ProMIS Neurosciences

AIM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AIM has been loosely correlated with CVAC. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AIM jumps, then CVAC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AIM
1D Price
Change %
AIM100%
+1.87%
CVAC - AIM
44%
Loosely correlated
+1.48%
URGN - AIM
39%
Loosely correlated
+0.73%
HOTH - AIM
33%
Loosely correlated
+10.00%
IBIO - AIM
32%
Poorly correlated
-0.04%
SGMT - AIM
30%
Poorly correlated
+3.83%
More